Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/192003
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Argilés, Guillem | - |
dc.contributor.author | Mulet, Nuria | - |
dc.contributor.author | Valladares Ayerbes, Manuel | - |
dc.contributor.author | Viéitez, José M. | - |
dc.contributor.author | Grávalos, Cristina | - |
dc.contributor.author | García Alfonso, Pilar | - |
dc.contributor.author | Santos, Cristina | - |
dc.contributor.author | Tobeña, María | - |
dc.contributor.author | García Paredes, Beatriz | - |
dc.contributor.author | Benavides, Manuel | - |
dc.contributor.author | Cano, María T. | - |
dc.contributor.author | Loupakis, Fotios | - |
dc.contributor.author | Rodríguez Garrote, Mercedes | - |
dc.contributor.author | Rivera, Fernando | - |
dc.contributor.author | Goldberg, Richard M. | - |
dc.contributor.author | Cremolini, Chiara | - |
dc.contributor.author | Bennouna, Jaafar | - |
dc.contributor.author | Ciardiello, Fortunato | - |
dc.contributor.author | Tabernero Caturla, Josep | - |
dc.contributor.author | Aranda, Enrique | - |
dc.contributor.author | Falcone, Alfredo | - |
dc.contributor.author | Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) | - |
dc.contributor.author | UNICANCER GI | - |
dc.contributor.author | The REARRANGE investigators | - |
dc.date.accessioned | 2023-01-09T11:48:26Z | - |
dc.date.available | 2023-01-09T11:48:26Z | - |
dc.date.issued | 2022-12-01 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | http://hdl.handle.net/2445/192003 | - |
dc.description.abstract | Purpose: The purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients.Patients and methods: Patients with mCRC and progression during or within 3 months following their last standard chemotherapy regimen were randomised to receive the approved dose of regorafenib of 160 mg QD (arm A) or 120 mg QD (arm B) administered as 3 weeks of treatment followed by 1 week off, or 160 mg QD 1 week on/1 week off (arm C). The primary end-point was the percentage of patients with G3/G4 treatment-related adverse events (AEs) in each arm.Results: There were 299 patients randomly assigned to arm A (n = 101), arm B (n = 99), or arm C (n = 99); 297 initiated treatments (arm A n = 100, arm B n = 98, arm C n = 99: pop-ulation for safety analyses). G3/4 treatment-related AEs occurred in 60%, 55%, and 54% of patients in arms A, B, and C, respectively. The most common G3/4 AEs were hypertension (19, 12, and 20 patients), fatigue (20, 14, and 15 patients), hypokalemia (11, 7, and 10 pa-tients), and hand-foot skin reaction (8, 7, and 3 patients). Median overall survival was 7.4 (IQR 4.0-13.7) months in arm A, 8.6 (IQR 3.8-13.4) in arm B, and 7.1 (IQR 4.4-12.4) in arm C.Conclusions: The alternative regorafenib dosing schedules were feasible and safe in patients with mCRC who had been previously treated with standard therapy. There was a higher nu-merical improvement on the most clinically relevant AEs in the intermittent dosing arm, particularly during the relevant first two cycles. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier BV | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.ejca.2022.09.037 | - |
dc.relation.ispartof | European Journal of Cancer, 2022, vol. 177, p. 154-163 | - |
dc.relation.uri | https://doi.org/10.1016/j.ejca.2022.09.037 | - |
dc.rights | cc by (c) Argilés, Guillem et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer colorectal | - |
dc.subject.classification | Metàstasi | - |
dc.subject.classification | Administració de medicaments | - |
dc.subject.other | Colorectal cancer | - |
dc.subject.other | Metastasis | - |
dc.subject.other | Administration of drugs | - |
dc.title | A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial) | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-12-28T13:35:54Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 36335783 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PIIS0959804922007808.pdf | 1.25 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License